{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:08:31Z","timestamp":1791558511785,"version":"4.3.4"},"reference-count":155,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s11095-026-04054-y","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T22:42:21Z","timestamp":1772577741000},"page":"1799-1820","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impurity Characterization Across Drug Development Stages: Analytical Methodologies and Regulatory Perspectives"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6766-6074","authenticated-orcid":false,"given":"Subathra","family":"Ramamoorthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"issue":"4","key":"4054_CR1","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1002\/jps.22376","volume":"100","author":"C Pan","year":"2011","unstructured":"Pan C, Liu F, Motto M. Identification of pharmaceutical impurities in formulated dosage forms. J Pharm Sci. 2011;100(4):1228\u201359. https:\/\/doi.org\/10.1002\/jps.22376.","journal-title":"J Pharm Sci"},{"issue":"2","key":"4054_CR2","doi-asserted-by":"publisher","DOI":"10.1208\/pt030206","volume":"3","author":"J Roy","year":"2002","unstructured":"Roy J. Pharmaceutical impurities\u2014a mini-review. AAPS PharmSciTech. 2002;3(2):E6. https:\/\/doi.org\/10.1208\/pt030206.","journal-title":"AAPS PharmSciTech"},{"key":"4054_CR3","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Impurities in new drug substances Q3A(R2). ICH Harmonised Guideline. 2006."},{"key":"4054_CR4","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Impurities in New Drug Products Q3B(R2). ICH Harmonised Guideline. 2006."},{"issue":"3","key":"4054_CR5","doi-asserted-by":"publisher","first-page":"302","DOI":"10.4103\/0110-5558.72422","volume":"1","author":"K Pilaniya","year":"2010","unstructured":"Pilaniya K, Chandrawanshi HK, Pilaniya U, Manchandani P, Jain P, Singh N. Recent trends in the impurity profile of pharmaceuticals. J Adv Pharm Technol Res. 2010;1(3):302\u201310. https:\/\/doi.org\/10.4103\/0110-5558.72422.","journal-title":"J Adv Pharm Technol Res"},{"issue":"4","key":"4054_CR6","first-page":"46","volume":"15","author":"S Patole","year":"2019","unstructured":"Patole S, Gosar A, Shaikh T. Impurities characterization in pharmaceuticals: a review. Int J Pharm Pharm Res. 2019;15(4):46\u201364.","journal-title":"Int J Pharm Pharm Res"},{"key":"4054_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2024.105715","volume":"153","author":"F Liu","year":"2024","unstructured":"Liu F. Safety assessment of drug impurities for patient safety: a comprehensive review. Regul Toxicol Pharmacol. 2024;153:105715. https:\/\/doi.org\/10.1016\/j.yrtph.2024.105715.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"4","key":"4054_CR8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41573-022-00633-x","volume":"22","author":"F Pognan","year":"2023","unstructured":"Pognan F, Beilmann M, Boonen HCM, Czich A, Dear G, Hewitt P, et al. The evolving role of investigative toxicology in the pharmaceutical industry. Nat Rev Drug Discov. 2023;22(4):317\u201335. https:\/\/doi.org\/10.1038\/s41573-022-00633-x.","journal-title":"Nat Rev Drug Discov"},{"key":"4054_CR9","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ejps.2015.12.007","volume":"87","author":"R Holm","year":"2016","unstructured":"Holm R, Elder DP. Analytical advances in pharmaceutical impurity profiling. Eur J Pharm Sci. 2016;87:118\u201335. https:\/\/doi.org\/10.1016\/j.ejps.2015.12.007.","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"4054_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2217\/nnm-2020-0472","volume":"16","author":"S Moitra","year":"2021","unstructured":"Moitra S, Bteich M, Martinez MN, McNeil SE, Weissig V. Tackling the challenges of nanomedicines: are we ready? Nanomedicine (Lond). 2021;16(4):289\u2013304. https:\/\/doi.org\/10.2217\/nnm-2020-0472.","journal-title":"Nanomedicine (Lond)"},{"issue":"9","key":"4054_CR11","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1021\/acs.chemrestox.4c00234","volume":"37","author":"KM Manchuri","year":"2024","unstructured":"Manchuri KM, Shaik MA, Gopireddy VSR, Sultana N, Gogineni S. Analytical methodologies to detect N-nitrosamine impurities in active pharmaceutical ingredients, drug products and other matrices. Chem Res Toxicol. 2024;37(9):1456\u201383. https:\/\/doi.org\/10.1021\/acs.chemrestox.4c00234.","journal-title":"Chem Res Toxicol"},{"key":"4054_CR12","unstructured":"Olsen BA, Sreedhara A, Baertschi SW. Impurity investigations by phases of drug and product development. Trends Anal Chem. 2017;1\u20137."},{"key":"4054_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2025.125625","volume":"681","author":"CL Mustoe","year":"2025","unstructured":"Mustoe CL, Turner AJ, Urwin SJ, Houson I, Feilden H, Markl D, et al. Quality by digital design to accelerate sustainable medicines development. Int J Pharm. 2025;681:125625. https:\/\/doi.org\/10.1016\/j.ijpharm.2025.125625.","journal-title":"Int J Pharm"},{"issue":"8","key":"4054_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2025.101248","volume":"15","author":"C Fu","year":"2025","unstructured":"Fu C, Chen Q. The future of pharmaceuticals: artificial intelligence in drug discovery and development. J Pharm Anal. 2025;15(8):101248. https:\/\/doi.org\/10.1016\/j.jpha.2025.101248.","journal-title":"J Pharm Anal"},{"issue":"4","key":"4054_CR15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/17518250903258150","volume":"2","author":"BW Cue","year":"2009","unstructured":"Cue BW, Zhang J. Green process chemistry in the pharmaceutical industry. Green Chem Lett Rev. 2009;2(4):193\u2013211. https:\/\/doi.org\/10.1080\/17518250903258150.","journal-title":"Green Chem Lett Rev"},{"issue":"8","key":"4054_CR16","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.13040\/IJPSR.0975-8232.8(8).3206-17","volume":"8","author":"AD Savkare","year":"2017","unstructured":"Savkare AD, Kalaskar PS, Sarode SK, Potkule ME. Recent advances in impurity profiling of pharmaceuticals. Int J Pharm Sci Res. 2017;8(8):3206\u201317. https:\/\/doi.org\/10.13040\/IJPSR.0975-8232.8(8).3206-17.","journal-title":"Int J Pharm Sci Res"},{"issue":"10","key":"4054_CR17","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.13040\/IJPSR.0975-8232.5(10).4078-08","volume":"5","author":"R Ghosh","year":"2014","unstructured":"Ghosh R, Darin K, Deb P. Presence of organic impurities into active pharmaceutical ingredients: a review. Int J Pharm Sci Res. 2014;5(10):4078\u2013108. https:\/\/doi.org\/10.13040\/IJPSR.0975-8232.5(10).4078-08.","journal-title":"Int J Pharm Sci Res"},{"issue":"5","key":"4054_CR18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.22270\/ajprd.v12i5.1477","volume":"12","author":"SR Mande","year":"2024","unstructured":"Mande SR, Yelmame SS, Borse LB. A review on impurity profiling in pharmaceutical substances. Asian J Pharm Res Dev. 2024;12(5):46\u201351. https:\/\/doi.org\/10.22270\/ajprd.v12i5.1477.","journal-title":"Asian J Pharm Res Dev"},{"issue":"2","key":"4054_CR19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.2174\/1570163813666161221141402","volume":"14","author":"M Mittal","year":"2017","unstructured":"Mittal M, Kumar K, Anghore D, Rawal RK. ICP-MS: analytical method for identification and detection of elemental impurities. Curr Drug Discov Technol. 2017;14(2):106\u201320. https:\/\/doi.org\/10.2174\/1570163813666161221141402.","journal-title":"Curr Drug Discov Technol"},{"key":"4054_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.643972","volume":"12","author":"M Balali-Mood","year":"2021","unstructured":"Balali-Mood M, Naseri K, Tahergorabi Z, Khazdair MR, Sadeghi M. Toxic mechanisms of five heavy metals: mercury, lead, chromium, cadmium, and arsenic. Front Pharmacol. 2021;12:643972. https:\/\/doi.org\/10.3389\/fphar.2021.643972.","journal-title":"Front Pharmacol"},{"key":"4054_CR21","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Elemental Impurities Q3D(R2). ICH Harmonised Guideline. 2022."},{"key":"4054_CR22","unstructured":"ICH Harmonised Tripartite Guideline. Impurities: guideline for residual solvents Q3C(R8). International Conference on Harmonisation. 2021."},{"issue":"10","key":"4054_CR23","doi-asserted-by":"publisher","first-page":"5039","DOI":"10.13040\/IJPSR.0975-8232.11(10).5039-52","volume":"11","author":"SB Lakhmapure","year":"2020","unstructured":"Lakhmapure SB, Kothari S, Lokhande MV. Validation of gas chromatography (GC) method for residual solvent in brompheniramine maleate API. Int J Pharm Sci Res. 2020;11(10):5039\u201352. https:\/\/doi.org\/10.13040\/IJPSR.0975-8232.11(10).5039-52.","journal-title":"Int J Pharm Sci Res"},{"issue":"3","key":"4054_CR24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.52711\/2231-5691.2021.00034","volume":"11","author":"AB Patel","year":"2021","unstructured":"Patel AB, Asnani AH, Vyas AJ, Patel NK, Patel AI, Lumbhani AN. A brief review on genotoxic impurities in pharmaceuticals. Asian J Pharm Res. 2021;11(3):187\u201393. https:\/\/doi.org\/10.52711\/2231-5691.2021.00034.","journal-title":"Asian J Pharm Res"},{"issue":"1","key":"4054_CR25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.yrtph.2013.05.001","volume":"67","author":"A Sutter","year":"2013","unstructured":"Sutter A, Amberg A, Boyer S, Brigo A, Robinson S, Schilter B, et al. Use of in silico systems and expert knowledge for structure-based assessment of potentially mutagenic impurities. Regul Toxicol Pharmacol. 2013;67(1):39\u201352. https:\/\/doi.org\/10.1016\/j.yrtph.2013.05.001.","journal-title":"Regul Toxicol Pharmacol"},{"key":"4054_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.yrtph.2016.02.004","volume":"77","author":"A Amberg","year":"2016","unstructured":"Amberg A, Beilke L, Bercu J, Bower D, Brigo A, Cross KP, et al. Principles and procedures for implementation of ICH M7-recommended (Q)SAR analyses. Regul Toxicol Pharmacol. 2016;77:13\u201324. https:\/\/doi.org\/10.1016\/j.yrtph.2016.02.004.","journal-title":"Regul Toxicol Pharmacol"},{"key":"4054_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2020.104749","volume":"116","author":"A Thresher","year":"2020","unstructured":"Thresher A, Foster R, Ponting DJ, Stalford SA, Tennant RE, Thomas R. Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data. Regul Toxicol Pharmacol. 2020;116:104749. https:\/\/doi.org\/10.1016\/j.yrtph.2020.104749.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"18","key":"4054_CR28","doi-asserted-by":"publisher","first-page":"9465","DOI":"10.3390\/ijerph18189465","volume":"18","author":"T Li","year":"2021","unstructured":"Li T, Cheng Y, Liu Q, Li P, Zhang H, Zhao J, et al. Estimated cancer risks associated with nitrosamine contamination in commonly used medications. Int J Environ Res Public Health. 2021;18(18):9465. https:\/\/doi.org\/10.3390\/ijerph18189465.","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"4054_CR29","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jsps.2022.12.010","volume":"31","author":"W Wichitnithad","year":"2023","unstructured":"Wichitnithad W, Nantaphol S, Noppakhunsomboon K, Rojsitthisak P. An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals. Saudi Pharm J. 2023;31(2):295\u2013311. https:\/\/doi.org\/10.1016\/j.jsps.2022.12.010.","journal-title":"Saudi Pharm J"},{"key":"4054_CR30","unstructured":"FDA Guidance for Industry. Container closure systems for packaging human drugs and biologics. U.S. Food and Drug Administration. 1999."},{"issue":"6","key":"4054_CR31","first-page":"332","volume":"56","author":"D Jenke","year":"2002","unstructured":"Jenke D. Extractable\/leachable substances from plastic materials used as pharmaceutical product containers\/devices. PDA J Pharm Sci Technol. 2002;56(6):332\u201371.","journal-title":"PDA J Pharm Sci Technol"},{"issue":"15","key":"4054_CR32","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jhazmat.2017.10.014","volume":"344","author":"JN Hahladakis","year":"2018","unstructured":"Hahladakis JN, Velis CA, Weber R, Iacovidou E, Purnell P. An overview of chemical additives present in plastics: migration, release, fate and environmental impact during their use, disposal and recycling. J Hazard Mater. 2018;344(15):179\u201399. https:\/\/doi.org\/10.1016\/j.jhazmat.2017.10.014.","journal-title":"J Hazard Mater"},{"key":"4054_CR33","unstructured":"U.S. Food and Drug Administration. Q3E Guideline for Extractables and Leachables. Draft guidance for industry. Silver Spring, MD: U.S. Food and Drug Administration; November 2025."},{"issue":"7","key":"4054_CR34","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1002\/jps.21180","volume":"97","author":"H Liu","year":"2008","unstructured":"Liu H, Gaza-Bulseco G, Faldu D, Chumsae C, Sun J. Heterogeneity of monoclonal antibodies. J Pharm Sci. 2008;97(7):2426\u201347. https:\/\/doi.org\/10.1002\/jps.21180.","journal-title":"J Pharm Sci"},{"issue":"2","key":"4054_CR35","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.2108","volume":"30","author":"BQ Shen","year":"2012","unstructured":"Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody\u2013drug conjugates. Nat Biotechnol. 2012;30(2):184\u20139. https:\/\/doi.org\/10.1038\/nbt.2108.","journal-title":"Nat Biotechnol"},{"key":"4054_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2021.724306","volume":"9","author":"K Pilely","year":"2021","unstructured":"Pilely K, Johansen MR, Raen L, Kofoed T. Monitoring process-related impurities in biologics\u2014host cell protein analysis. Front Bioeng Biotechnol. 2021;9:724306. https:\/\/doi.org\/10.3389\/fbioe.2021.724306.","journal-title":"Front Bioeng Biotechnol"},{"key":"4054_CR37","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10616-007-9075-2","volume":"53","author":"N Jenkins","year":"2007","unstructured":"Jenkins N. Modifications of therapeutic proteins: challenges and prospects. Cytotechnology. 2007;53:121\u20135. https:\/\/doi.org\/10.1007\/s10616-007-9075-2.","journal-title":"Cytotechnology"},{"issue":"15","key":"4054_CR38","doi-asserted-by":"publisher","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","volume":"10","author":"KJ Hamblett","year":"2004","unstructured":"Hamblett KJ, Senter PD, Chace DF, Sun MMC, Lenox J, Cerveny CG, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10(15):7063\u201370. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0789.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4054_CR39","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/biot.201200018","volume":"8","author":"AL Tscheliessnig","year":"2013","unstructured":"Tscheliessnig AL, Konrath J, Bates R, Jungbauer A. Host cell protein analysis in therapeutic protein bioprocessing \u2013 methods and applications. Biotechnol J. 2013;8(6):655\u201370. https:\/\/doi.org\/10.1002\/biot.201200018.","journal-title":"Biotechnol J"},{"issue":"3","key":"4054_CR40","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/bit.22304","volume":"103","author":"X Wang","year":"2009","unstructured":"Wang X, Hunter AK, Mozier NM. Host cell proteins in biologics development: identification, quantitation and risk assessment. Biotechnol Bioeng. 2009;103(3):446\u201358. https:\/\/doi.org\/10.1002\/bit.22304.","journal-title":"Biotechnol Bioeng"},{"issue":"3","key":"4054_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2024.105715","volume":"153","author":"F Liu","year":"2024","unstructured":"Liu F. Safety assessment of drug impurities for patient safety: a comprehensive review. Regul Toxicol Pharmacol. 2024;153(3):105715. https:\/\/doi.org\/10.1016\/j.yrtph.2024.105715.","journal-title":"Regul Toxicol Pharmacol"},{"key":"4054_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2021.104890","volume":"122","author":"F Pretto","year":"2021","unstructured":"Pretto F, FitzGerald RE. In vivo safety testing of antibody drug conjugates. Regul Toxicol Pharmacol. 2021;122:104890. https:\/\/doi.org\/10.1016\/j.yrtph.2021.104890.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"3","key":"4054_CR43","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.jpba.2008.06.009","volume":"48","author":"DP Elder","year":"2008","unstructured":"Elder DP, Lipczynski AM, Teasdale A. Control and analysis of alkyl and benzyl halides and other related organohalides as potential genotoxic impurities in active pharmaceutical ingredients (APIs). J Pharm Biomed Anal. 2008;48(3):497\u2013507. https:\/\/doi.org\/10.1016\/j.jpba.2008.06.009.","journal-title":"J Pharm Biomed Anal"},{"issue":"5","key":"4054_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17050623","volume":"17","author":"S Yang","year":"2025","unstructured":"Yang S, Hu X, Zhu J, Zheng B, Bi W, Wang X, et al. Aspects and implementation of pharmaceutical quality by design from conceptual frameworks to industrial applications. Pharmaceutics. 2025;17(5):623. https:\/\/doi.org\/10.3390\/pharmaceutics17050623.","journal-title":"Pharmaceutics"},{"key":"4054_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2024.105645","volume":"150","author":"C Hasselgren","year":"2024","unstructured":"Hasselgren C, Kenyon M, Anger LT, Cornwell P, Watt E, Bercu J. Analysis of non-mutagenic substances in the context of drug impurity assessment\u2014few are potent toxicants. Regul Toxicol Pharmacol. 2024;150:105645. https:\/\/doi.org\/10.1016\/j.yrtph.2024.105645.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"4","key":"4054_CR46","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/clpt.2011.10","volume":"89","author":"JA Molzon","year":"2011","unstructured":"Molzon JA, Giaquinto A, Lindstrom L, et al. The value and benefits of the International Conference on Harmonisation to drug regulatory authorities: advancing harmonization for better public health. Clin Pharmacol Ther. 2011;89(4):503\u201312. https:\/\/doi.org\/10.1038\/clpt.2011.10.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"4054_CR47","doi-asserted-by":"publisher","first-page":"299","DOI":"10.5530\/ijpi.14.2.37","volume":"14","author":"SJ Dsouza","year":"2024","unstructured":"Dsouza SJ, Sandeep DS, Charyulu RN, Gowrav MP, Pradeep HK. Impurities in drug substance\u2014an overview of ICH Q3A, Q3C and M7 guidelines. Int J Pharm Investig. 2024;14(2):299\u2013305.","journal-title":"Int J Pharm Investig"},{"key":"4054_CR48","series-title":"Development and validation of analytical methods","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/B978-0-443-13466-1.00006-4","volume-title":"Specification of drug substances and products","author":"CM Riley","year":"2025","unstructured":"Riley CM, Nguyen KL, Gellermann G, Kirsch S. Introduction. In: Specification of drug substances and products. 3rd ed. Development and validation of analytical methods. Amsterdam: Elsevier; 2025. p. 3\u201318. https:\/\/doi.org\/10.1016\/B978-0-443-13466-1.00006-4.","edition":"3"},{"key":"4054_CR49","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances Q6A. ICH Harmonised Guideline. 1999."},{"key":"4054_CR50","unstructured":"International Council for Harmonisation. ICH Harmonised Tripartite Guideline Q6B: Specifications: Test Procedures and Acceptance Criteria for Biotechnological\/Biological Products. ICH; 1999"},{"key":"4054_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2022.114709","volume":"214","author":"PS Achanta","year":"2022","unstructured":"Achanta PS, Niemitz M, Friesen JB, Tadjimukhamedov FK, Bzhelyansky A, Giancaspro GI, et al. Pharmaceutical analysis by NMR can accommodate strict impurity thresholds: the case of choline. J Pharm Biomed Anal. 2022;214:114709. https:\/\/doi.org\/10.1016\/j.jpba.2022.114709.","journal-title":"J Pharm Biomed Anal"},{"issue":"2","key":"4054_CR52","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/10408347.2016.1169913","volume":"46","author":"B Ramachandra","year":"2016","unstructured":"Ramachandra B. Development of impurity profiling methods using modern analytical techniques. Crit Rev Anal Chem. 2016;46(2):24\u201336. https:\/\/doi.org\/10.1080\/10408347.2016.1169913.","journal-title":"Crit Rev Anal Chem"},{"key":"4054_CR53","unstructured":"O\u2019Connor D, McElvain JS. Early development GMPs for small-molecule specifications: An industry perspective (Part V). Pharmaceutical Technology. 2012;36(10)."},{"key":"4054_CR54","unstructured":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Office of Generic Drugs (OGD). Guidance for Industry: ANDAs\u2014Impurities in Drug Products. Rockville (MD): U.S. Food and Drug Administration; 2010 Nov. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents"},{"key":"4054_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2019.104524","volume":"110","author":"L Weidolf","year":"2020","unstructured":"Weidolf L, Andersson T, Bercu JP, Brink A, Glowienke S, Harvey J, et al. Qualification of impurities based on metabolite data. Regul Toxicol Pharmacol. 2020;110:104524. https:\/\/doi.org\/10.1016\/j.yrtph.2019.104524.","journal-title":"Regul Toxicol Pharmacol"},{"key":"4054_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2024.105644","volume":"150","author":"MO Kenyon","year":"2024","unstructured":"Kenyon MO, Martin M, Martin EA, Brandstetter S, Wegesser T, Greene N, et al. Deriving acceptable limits for non-mutagenic impurities in medicinal products \u2013 durational adjustments. Regul Toxicol Pharmacol. 2024;150:105644. https:\/\/doi.org\/10.1016\/j.yrtph.2024.105644.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"5","key":"4054_CR57","doi-asserted-by":"publisher","DOI":"10.1093\/toxres\/tfae178","volume":"13","author":"CJ Waine","year":"2024","unstructured":"Waine CJ, Watts P, Hopkins J. The cliff-edge of toxicological concern: highlighting the potential issues of an over-reliance on \u201cless-than-lifetime\u201d thresholds. Toxicol Res. 2024;13(5):tfae178. https:\/\/doi.org\/10.1093\/toxres\/tfae178.","journal-title":"Toxicol Res"},{"key":"4054_CR58","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Assessment and control of DNA reactive (Mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk M7. ICH Harmonised Guideline. 2014."},{"key":"4054_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2023.105403","volume":"141","author":"DJ Snodin","year":"2023","unstructured":"Snodin DJ. Mutagenic impurities in pharmaceuticals: a critical assessment of the cohort of concern with a focus on N-nitrosamines. Regul Toxicol Pharmacol. 2023;141:105403. https:\/\/doi.org\/10.1016\/j.yrtph.2023.105403.","journal-title":"Regul Toxicol Pharmacol"},{"key":"4054_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpbao.2025.100084","volume":"6","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Widart J, Ziemons E, Hubert P, Hubert C. N-nitrosamine risk assessment in pharmaceuticals: where are we from a regulatory point of view in 2025? Journal of Pharmaceutical and Biomedical Analysis Open. 2025;6:100084. https:\/\/doi.org\/10.1016\/j.jpbao.2025.100084.","journal-title":"Journal of Pharmaceutical and Biomedical Analysis Open"},{"key":"4054_CR61","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Nonclinical evaluation for anticancer pharmaceuticals S9. ICH Harmonised Guideline (Step 4 version). 2009."},{"key":"4054_CR62","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s12247-018-9366-5","volume":"14","author":"J Bercu","year":"2019","unstructured":"Bercu J, Berlam SC, Berridge J, et al. Establishing patient centric specifications for drug substance and drug product impurities. J Pharm Innov. 2019;14:76\u201389. https:\/\/doi.org\/10.1007\/s12247-018-9366-5.","journal-title":"J Pharm Innov"},{"key":"4054_CR63","doi-asserted-by":"publisher","unstructured":"Singh D, Isharani R. A Detailed Review on Analytical Methods to Manage the Impurities in Drug Substances. Open Access Libr J. 2023;10(8). https:\/\/doi.org\/10.4236\/oalib.1110223.","DOI":"10.4236\/oalib.1110223"},{"key":"4054_CR64","doi-asserted-by":"publisher","DOI":"10.26717\/BJSTR.2022.40.006521","volume":"40","author":"S Singh","year":"2022","unstructured":"Singh S. Recent trends in analytical techniques for impurity profiling. Biomedical Journal of Scientific & Technical Research. 2022;40:006521. https:\/\/doi.org\/10.26717\/BJSTR.2022.40.006521.","journal-title":"Biomedical Journal of Scientific & Technical Research"},{"issue":"1","key":"4054_CR65","doi-asserted-by":"publisher","DOI":"10.54517\/aas3159","volume":"6","author":"S Anwar","year":"2025","unstructured":"Anwar S, Khan A, Jamal M, Siddiqui MZ. Review on the modern analytical advancements in impurities testing. Advances in Analytic Science. 2025;6(1):3159. https:\/\/doi.org\/10.54517\/aas3159.","journal-title":"Advances in Analytic Science"},{"key":"4054_CR66","unstructured":"Dong MW, Kim Huynh-Ba, Ayers JT. Development of stability-indicating analytical procedures by HPLC: An overview and best practices. LCGC North America. 2020;38(8)."},{"issue":"2","key":"4054_CR67","doi-asserted-by":"publisher","first-page":"5","DOI":"10.17305\/bjbms.2004.3405","volume":"4","author":"B Nikolin","year":"2004","unstructured":"Nikolin B, Imamovi\u0107 B, Medanhod\u017ei\u0107-Vuk S, Sober M. High performance liquid chromatography in pharmaceutical analyses. Bosn J Basic Med Sci. 2004;4(2):5\u20139. https:\/\/doi.org\/10.17305\/bjbms.2004.3405.","journal-title":"Bosn J Basic Med Sci"},{"issue":"6","key":"4054_CR68","doi-asserted-by":"publisher","first-page":"039","DOI":"10.69613\/t4nhz921","volume":"2","author":"T Vanitha Madhuri","year":"2024","unstructured":"Vanitha Madhuri T. Advances in high-performance liquid chromatography (HPLC) and ultra-performance liquid chromatography (UPLC): review article. J Pharma Insights Res. 2024;2(6):039\u201346. https:\/\/doi.org\/10.69613\/t4nhz921.","journal-title":"J Pharma Insights Res"},{"key":"4054_CR69","doi-asserted-by":"publisher","unstructured":"Deta SI. HPLC Method Development and Impurity Profiling. Analytical And Process Development with Quality by Design. Afr J Biomed Res. 2024;27(4S). https:\/\/doi.org\/10.53555\/AJBR.v27i4S.3802.","DOI":"10.53555\/AJBR.v27i4S.3802"},{"issue":"21","key":"4054_CR70","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s10337-013-2434-6","volume":"76","author":"J Cielecka-Piontek","year":"2013","unstructured":"Cielecka-Piontek J, Zalewski P, Jeli\u0144ska A, Garbacki P. UHPLC: the greening face of liquid chromatography. Chromatographia. 2013;76(21):1429\u201337. https:\/\/doi.org\/10.1007\/s10337-013-2434-6.","journal-title":"Chromatographia"},{"issue":"2","key":"4054_CR71","doi-asserted-by":"publisher","first-page":"111","DOI":"10.5487\/TR.2018.34.2.111","volume":"34","author":"L Romanelli","year":"2018","unstructured":"Romanelli L, Evandri MG. Permitted daily exposure for diisopropyl ether as a residual solvent in pharmaceuticals. Toxicol Res. 2018;34(2):111\u201325. https:\/\/doi.org\/10.5487\/TR.2018.34.2.111.","journal-title":"Toxicol Res"},{"issue":"2","key":"4054_CR72","first-page":"32","volume":"21","author":"I Pinar","year":"2025","unstructured":"Pinar I, Sweatman J. Generic method approach for the determination of residual solvents in active pharmaceutical ingredients by gas chromatography. LCGC North Am. 2025;21(2):32\u20136.","journal-title":"LCGC North Am"},{"issue":"3","key":"4054_CR73","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1023\/A:1022693516409","volume":"20","author":"C B\u2019Hymer","year":"2003","unstructured":"B\u2019Hymer C. Residual solvent testing: a review of gas-chromatographic and alternative techniques. Pharm Res. 2003;20(3):337\u201344.","journal-title":"Pharm Res"},{"issue":"1","key":"4054_CR74","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jpha.2021.06.009","volume":"12","author":"M Shah","year":"2021","unstructured":"Shah M, Patel N, Tripathi N, Vyas VK. Capillary electrophoresis methods for impurity profiling of drugs: a review of the past decade. J Pharm Anal. 2021;12(1):15\u201328. https:\/\/doi.org\/10.1016\/j.jpha.2021.06.009.","journal-title":"J Pharm Anal"},{"key":"4054_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.aca.2024.342889","volume":"1323","author":"T Jankech","year":"2024","unstructured":"Jankech T, Gerhardtova I, Stefanik O, Chalova P, Jampilek J, Majerova P, et al. Current green capillary electrophoresis and liquid chromatography methods for analysis of pharmaceutical and biomedical samples (2019\u20132023) \u2013 a review. Anal Chim Acta. 2024;1323:342889. https:\/\/doi.org\/10.1016\/j.aca.2024.342889.","journal-title":"Anal Chim Acta"},{"issue":"1","key":"4054_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-51233-6","volume":"9","author":"L Gentiluomo","year":"2019","unstructured":"Gentiluomo L, Schneider V, Roessner D, Frie\u00df W. Coupling multi-angle light scattering to reverse-phase ultra-high-pressure chromatography (RP-UPLC-MALS) for the characterization monoclonal antibodies. Sci Rep. 2019;9(1):14965. https:\/\/doi.org\/10.1038\/s41598-019-51233-6.","journal-title":"Sci Rep"},{"issue":"2","key":"4054_CR77","doi-asserted-by":"publisher","first-page":"161","DOI":"10.4161\/mabs.3.2.14854","volume":"3","author":"A Wakankar","year":"2011","unstructured":"Wakankar A, Chen Y, Gokarn Y, Jacobson FS. Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs. 2011;3(2):161\u201372. https:\/\/doi.org\/10.4161\/mabs.3.2.14854.","journal-title":"MAbs"},{"key":"4054_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.aca.2024.343176","volume":"1328","author":"C Leng","year":"2024","unstructured":"Leng C, Sun S, Lin W, Pavon JA, Gennaro L, Gunawan RC, et al. Imaged capillary isoelectric focusing method development for charge variants of high DAR ADCs. Anal Chim Acta. 2024;1328:343176. https:\/\/doi.org\/10.1016\/j.aca.2024.343176.","journal-title":"Anal Chim Acta"},{"issue":"2","key":"4054_CR79","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s00216-021-03648-2","volume":"414","author":"K Pilely","year":"2021","unstructured":"Pilely K, Johansen MR, Lund RR, Kofoed T, J\u00f8rgensen TK, Skriver L, et al. Monitoring process-related impurities in biologics\u2013host cell protein analysis. Anal Bioanal Chem. 2021;414(2):747\u201358. https:\/\/doi.org\/10.1007\/s00216-021-03648-2.","journal-title":"Anal Bioanal Chem"},{"key":"4054_CR80","doi-asserted-by":"publisher","DOI":"10.1002\/bit.28112","author":"F Wang","year":"2022","unstructured":"Wang F, Li X, Swanson M, Guetschow E, Winston M, Smith JP, et al. Holistic analytical characterization and risk assessment of residual host cell protein impurities in an active pharmaceutical ingredient synthesized by biocatalysts. Biotechnol Bioeng. 2022. https:\/\/doi.org\/10.1002\/bit.28112.","journal-title":"Biotechnol Bioeng"},{"issue":"12","key":"4054_CR81","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1080\/10826076.2010.484356","volume":"28","author":"ME Swartz","year":"2010","unstructured":"Swartz ME. HPLC detectors: a brief review. LCGC North Am. 2010;28(12):1130\u201350. https:\/\/doi.org\/10.1080\/10826076.2010.484356.","journal-title":"LCGC North Am"},{"issue":"8","key":"4054_CR82","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.trac.2006.05.012","volume":"25","author":"SW Baertschi","year":"2006","unstructured":"Baertschi SW. Analytical methodologies for discovering and profiling degradation-related impurities. TrAC Trends Anal Chem. 2006;25(8):758\u201367. https:\/\/doi.org\/10.1016\/j.trac.2006.05.012.","journal-title":"TrAC Trends Anal Chem"},{"issue":"1","key":"4054_CR83","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4103\/2229-4708.72222","volume":"1","author":"KN Patel","year":"2010","unstructured":"Patel KN, Patel JK, Patel MP, Rajput GC, Patel HA. Introduction to hyphenated techniques and their applications in pharmacy. Pharm Methods. 2010;1(1):2\u201313. https:\/\/doi.org\/10.4103\/2229-4708.72222.","journal-title":"Pharm Methods"},{"key":"4054_CR84","unstructured":"Workman J Jr. Advancements and emerging techniques in mass spectrometry: A comprehensive review. LCGC North America Supplement. 2024; Hot Topics in Mass Spectrometry:22\u201327."},{"issue":"1","key":"4054_CR85","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1021\/ctm.1c00010","volume":"21","author":"\u0141 Rajski","year":"2023","unstructured":"Rajski \u0141, Kutscher D, Roberts D. Untargeted screening and identification of contaminants using gas chromatography coupled to high-resolution accurate mass\u2013mass spectrometry: novel solutions for applied testing laboratories. Curr Trends Mass Spectrom. 2023;21(1):8\u201316. https:\/\/doi.org\/10.1021\/ctm.1c00010.","journal-title":"Curr Trends Mass Spectrom"},{"key":"4054_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.trac.2021.116286","volume":"141","author":"G Singh","year":"2021","unstructured":"Singh G, Lu D, Liu C, Hower D. Analytical challenges and recent advances in the identification and quantitation of extractables and leachables in pharmaceutical and medical products. TrAC Trends Anal Chem. 2021;141:116286. https:\/\/doi.org\/10.1016\/j.trac.2021.116286.","journal-title":"TrAC Trends Anal Chem"},{"key":"4054_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpbao.2025.100063","volume":"5","author":"CR Andriolli","year":"2025","unstructured":"Andriolli CR, Nascimento MS, Henn AS, Flores ELM, Moraes Flores EM, Picoloto RS. A novel microextraction method for further elemental impurity determination in oily pharmaceutical excipients by ICP-MS. J Pharm Biomed Anal Open. 2025;5:100063. https:\/\/doi.org\/10.1016\/j.jpbao.2025.100063.","journal-title":"J Pharm Biomed Anal Open"},{"key":"4054_CR88","doi-asserted-by":"publisher","DOI":"10.1002\/mas.21575","author":"RM Gathungu","year":"2018","unstructured":"Gathungu RM, Kautz R, Kristal BS, Bird SS, Vouros P. The integration of LC-MS and NMR for the analysis of low molecular weight trace analytes in complex matrices. Mass Spectrom Rev. 2018. https:\/\/doi.org\/10.1002\/mas.21575.","journal-title":"Mass Spectrom Rev"},{"issue":"6","key":"4054_CR89","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1021\/np500206q","volume":"77","author":"GF Pauli","year":"2014","unstructured":"Pauli GF, Chen SN, Lankin DC, Bisson J, Case RJ, Chadwick LR, et al. Essential parameters for structural analysis and dereplication by 1H NMR spectroscopy. J Nat Prod. 2014;77(6):1473\u201387. https:\/\/doi.org\/10.1021\/np500206q.","journal-title":"J Nat Prod"},{"issue":"1","key":"4054_CR90","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3797\/scipharm.1407-18","volume":"83","author":"L Prakash","year":"2014","unstructured":"Prakash L, Himaja M, Vasudev R. Isolation, identification, and characterisation of degradation products and the development and validation of a stability-indicating method for the estimation of impurities in the tolterodine tartrate formulation. Sci Pharm. 2014;83(1):65\u201383. https:\/\/doi.org\/10.3797\/scipharm.1407-18.","journal-title":"Sci Pharm"},{"issue":"3","key":"4054_CR91","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s40268-017-0196-6","volume":"17","author":"K Egusa","year":"2017","unstructured":"Egusa K, Okazaki F, Schiewe J, Werthmann U, Wolkenhauer M. Identification of polymorphic forms of active pharmaceutical ingredient in low-concentration dry powder formulations by synchrotron X-ray powder diffraction. Drugs R D. 2017;17(3):413\u20138. https:\/\/doi.org\/10.1007\/s40268-017-0196-6.","journal-title":"Drugs R D"},{"key":"4054_CR92","unstructured":"Kumar S, Praveen Kumar VA, Rao U. Recent approaches for impurity profiling in pharmaceutical formulations. Int J Pharm Res Allied Sci. 2013;2(3):1\u20139. Available from: http:\/\/ijpra.com"},{"key":"4054_CR93","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.trac.2017.10.025","volume":"101","author":"BA Olsen","year":"2018","unstructured":"Olsen BA, Sreedhara A, Baertschi SW. Impurity investigations by phases of drug and product development. TrAC Trends Anal Chem. 2018;101:17\u201323. https:\/\/doi.org\/10.1016\/j.trac.2017.10.025.","journal-title":"TrAC Trends Anal Chem"},{"key":"4054_CR94","unstructured":"Sofpromed. An Introduction to Analytical Method Development and Validation in Early Phase Clinical Trials [Internet]. 2023 [cited 2025 Oct 10]. Available from: https:\/\/www.sofpromed.com\/an-introduction-to-analytical-method-development-and-validation-in-early-phase-clinical-trials"},{"key":"4054_CR95","unstructured":"CleanChem Laboratories. Impurity Reference Standards [Internet]. 2025 [cited 2025 Oct 10]. Available from: https:\/\/www.cleanchemlab.com\/service-details\/impurity-reference-standards"},{"key":"4054_CR96","unstructured":"Rushing W. Designing Phase-Appropriate CMC Analytical Programs. Pharm Technol [Internet]. 2019 Aug [cited 2025 Oct 10]. Available from: https:\/\/www.pharmtech.com\/view\/designing-phase-appropriate-cmc-analytical-programs"},{"key":"4054_CR97","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Validation of analytical procedures: text and methodology Q2(R1). ICH Harmonised Guideline. 2005."},{"key":"4054_CR98","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Stability testing of new drug substances and products Q1A(R2). ICH Harmonised Guideline. 2003."},{"key":"4054_CR99","unstructured":"U.S. Food and Drug Administration. INDs for phase 2 and phase 3 studies: Chemistry, manufacturing, and controls information. Rockville, MD: FDA; 2003. Available at:\u00a0https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/inds-phase-2-and-phase-3-studies-chemistry-manufacturing-and-controls-information."},{"key":"4054_CR100","unstructured":"European Medicines Agency. Guideline on the requirements for the chemical and pharmaceutical quality documentation concerning investigational medicinal products in clinical trials (Revision 2). EMA\/CHMP\/QWP\/805697\/2012 Rev 2. London: EMA; 2018. Available at:\u00a0https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-requirements-chemical-pharmaceutical-quality-documentation-concerning-investigational_en.pdf."},{"key":"4054_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2024.105647","volume":"150","author":"A Slikkerveer","year":"2024","unstructured":"Slikkerveer A, Doehr O, Claude N, Hutchinson R, Harvey J, Spanhaak S. New limits proposed for the management of non-mutagenic impurities. Regul Toxicol Pharmacol. 2024;150:105647. https:\/\/doi.org\/10.1016\/j.yrtph.2024.105647.","journal-title":"Regul Toxicol Pharmacol"},{"key":"4054_CR102","unstructured":"Vici Health Sciences. Phase Appropriate Method Validation in Drug Development [Internet]. 2024 [cited 2025 Oct 10]. Available from: https:\/\/vicihealthsciences.com\/phase-appropriate-method-validation\/"},{"key":"4054_CR103","unstructured":"Labinsights.nl. A Comprehensive Guide to Impurity Reference Standards and Comparison Standards: Definitions, Functions, and Uses [Internet]. 2024 [cited 2025 Oct 10]. Available from: https:\/\/labinsights.nl\/en\/article\/a-comprehensive-guide-to-impurity-reference-standards-and-comparison-standards-definitions-functions-and-uses"},{"issue":"1","key":"4054_CR104","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.13040\/IJPSR.0975-8232.12(1).2601-9","volume":"12","author":"P Nargatti","year":"2021","unstructured":"Nargatti P, Mullani A. Forced degradation study \u2013 a new approach for stress testing of drug substances and drug products. Int J Pharm Sci Res. 2021;12(1):2601\u20139. https:\/\/doi.org\/10.13040\/IJPSR.0975-8232.12(1).2601-9.","journal-title":"Int J Pharm Sci Res"},{"key":"4054_CR105","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.trac.2017.10.021","volume":"101","author":"DK Singh","year":"2018","unstructured":"Singh DK, Sahu A, Kumar S, Singh S. Critical review on establishment and availability of impurity and degradation product reference standards, challenges faced by the users, recent developments, and trends. TrAC Trends Anal Chem. 2018;101:85\u2013107. https:\/\/doi.org\/10.1016\/j.trac.2017.10.021.","journal-title":"TrAC Trends Anal Chem"},{"issue":"1","key":"4054_CR106","doi-asserted-by":"publisher","DOI":"10.1038\/s43586-022-00175-x","volume":"2","author":"SN Thomas","year":"2022","unstructured":"Thomas SN, French D, Jannetto PJ, Rappold BA, Clarke WA. Liquid chromatography\u2013tandem mass spectrometry for clinical diagnostics. Nat Rev Methods Primers. 2022;2(1):96. https:\/\/doi.org\/10.1038\/s43586-022-00175-x.","journal-title":"Nat Rev Methods Primers"},{"key":"4054_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.119018","volume":"576","author":"D Pokar","year":"2020","unstructured":"Pokar D, Rajput N, Sengupta P. Industrial approaches and consideration of clinical relevance in setting impurity level specification for drug substances and drug products. Int J Pharm. 2020;576:119018. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.119018.","journal-title":"Int J Pharm"},{"issue":"2","key":"4054_CR108","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.6069","volume":"39","author":"RRJ Reddy","year":"2025","unstructured":"Reddy RRJ, Kolli SK, Salakolusu S, Kallam SDM, Raghupathi JK, Katari NK. Characterization and analytical method validation for potential impurities of a merchantability drug substance fluoxetine HCl. Biomed Chromatogr. 2025;39(2):e6069. https:\/\/doi.org\/10.1002\/bmc.6069.","journal-title":"Biomed Chromatogr"},{"key":"4054_CR109","unstructured":"U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER). Guidance for industry: CMC postapproval manufacturing changes to be documented in annual reports. Silver Spring, MD: FDA; 2014."},{"key":"4054_CR110","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1208\/s12248-025-01079-w","volume":"27","author":"JG Duarte","year":"2025","unstructured":"Duarte JG, Duarte MG, Piedade AP, Mascarenhas-Melo F. Rethinking the pharmaceutical industry with quality by design: application in research, development, manufacturing, and quality assurance. AAPS J. 2025;27:96. https:\/\/doi.org\/10.1208\/s12248-025-01079-w.","journal-title":"AAPS J."},{"key":"4054_CR111","unstructured":"International Council for Harmonisation (ICH). Q9(R1): Quality Risk Management. Geneva: ICH; 2023."},{"key":"4054_CR112","unstructured":"Creaner G, Fitzgerald D. Quality risk management in the pharma \u2013 view 8 QRM tools [Internet]. GetReskilled; 2024. Available from: https:\/\/www.getreskilled.com\/validation\/risk-management-tools\/."},{"key":"4054_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2023.114174","volume":"195","author":"A Sim\u00f5es","year":"2024","unstructured":"Sim\u00f5es A, Veiga F, Vitorino C. Question-based review for pharmaceutical development: an enhanced quality approach. Eur J Pharm Biopharm. 2024;195:114174. https:\/\/doi.org\/10.1016\/j.ejpb.2023.114174.","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"4054_CR114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.17344\/acsi.2016.2840","volume":"64","author":"N Kragelj Lapanja","year":"2017","unstructured":"Kragelj Lapanja N, Toplak \u010casar R, Jurca S, Doljak B. Theoretical purge factor determination as a control strategy for potential mutagenic impurities in the synthesis of drug substances. Acta Chim Slov. 2017;64(1):1\u201314. https:\/\/doi.org\/10.17344\/acsi.2016.2840.","journal-title":"Acta Chim Slov"},{"key":"4054_CR115","unstructured":"International Conference on Harmonisation (ICH). Q8(R2): Pharmaceutical Development. Geneva: ICH; 2009."},{"key":"4054_CR116","doi-asserted-by":"publisher","first-page":"100084","DOI":"10.1016\/j.jpbao.2025.100084","volume":"6","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Widart J, Ziemons E, Hubert P, Hubert C. N-nitrosamine risk assessment in pharmaceuticals: where are we from a regulatory point of view in 2025? J Pharm Biomed Anal Open. 2025;6:100084. https:\/\/doi.org\/10.1016\/j.jpbao.2025.100084.","journal-title":"J Pharm Biomed Anal Open."},{"key":"4054_CR117","doi-asserted-by":"publisher","unstructured":"Cioc RC, Joyce C, Mayr M, Bream RN. Formation of N-nitrosamine drug substance related impurities in medicines: A regulatory perspective on risk factors and mitigation strategies. Org Process Res Dev. 2023 Jul 21;27(10). https:\/\/doi.org\/10.1021\/acs.oprd.3c00224.","DOI":"10.1021\/acs.oprd.3c00224"},{"key":"4054_CR118","unstructured":"U.S. Food and Drug Administration (FDA). Control of Nitrosamine Impurities in Human Drugs: Guidance for Industry. Rockville (MD): FDA; 2023."},{"key":"4054_CR119","unstructured":"European Medicines Agency (EMA). Questions and Answers: Nitrosamine Contamination of Human Medicinal Products. Amsterdam: EMA; 2023."},{"key":"4054_CR120","doi-asserted-by":"publisher","first-page":"100064","DOI":"10.1016\/j.jpbao.2025.100064","volume":"5","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Houari S, Van Laethem T, Dispas A, Ziemons E, Hubert P, et al. Innovative QSRR modeling approach for the development of an ultra-sensitive LC-MS\/MS method for trace analysis of N-nitrosamines. J Pharm Biomed Anal Open. 2025;5:100064. https:\/\/doi.org\/10.1016\/j.jpbao.2025.100064.","journal-title":"J Pharm Biomed Anal Open."},{"issue":"6","key":"4054_CR121","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1021\/acs.oprd.5c00097","volume":"29","author":"O Dirat","year":"2025","unstructured":"Dirat O, Urquhart MW, Akehurst H, Burns MJ, Dobo KL, Harvey J, et al. Drug substance and drug product workflows for quality risk management for the presence of nitrosamines in medicines. Org Process Res Dev. 2025;29(6):1538\u201353. https:\/\/doi.org\/10.1021\/acs.oprd.5c00097.","journal-title":"Org Process Res Dev"},{"issue":"11","key":"4054_CR122","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.5c00158","volume":"29","author":"A Tarafder","year":"2025","unstructured":"Tarafder A. Nitrosamine control: from risk assessment to analytical testing with emphasis on sample preparation and phase-appropriate method validation. Org Process Res Dev. 2025;29(11):e5c00158. https:\/\/doi.org\/10.1021\/acs.oprd.5c00158.","journal-title":"Org Process Res Dev"},{"key":"4054_CR123","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1415266","volume":"15","author":"AH G\u00f6ller","year":"2024","unstructured":"G\u00f6ller AH, Johanssen S, Zalewski A, Ziegler V. Quantum chemical calculations of nitrosamine activation and deactivation pathways for carcinogenicity risk assessment. Front Pharmacol. 2024;15:1415266. https:\/\/doi.org\/10.3389\/fphar.2024.1415266.","journal-title":"Front Pharmacol"},{"issue":"1","key":"4054_CR124","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1021\/acs.oprd.3c00404","volume":"28","author":"S Diab","year":"2024","unstructured":"Diab S, Dominey AP, Ferrini P, Hayler J, Hermitage S, Urquhart MW, et al. Formation of N-nitrosamines by reaction of secondary dialkylamines with trace levels of nitrite in aqueous solution: an automated experimental and kinetic modeling study using di-n-butylamine. Org Process Res Dev. 2024;28(1):293\u2013304. https:\/\/doi.org\/10.1021\/acs.oprd.3c00404.","journal-title":"Org Process Res Dev"},{"key":"4054_CR125","unstructured":"International Council for Harmonisation (ICH). Q10: Pharmaceutical Quality System. Geneva: ICH; 2008."},{"issue":"2","key":"4054_CR126","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jpba.2011.05.030","volume":"56","author":"S Thomas","year":"2011","unstructured":"Thomas S, Mathela CS, Agarwal A, Paul SK. Identification and structural elucidation of an unknown impurity in carbamazepine active pharmaceutical ingredient by liquid chromatography\u2013tandem mass spectrometry and semi-preparative chromatographic isolation. J Pharm Biomed Anal. 2011;56(2):10\u20138. https:\/\/doi.org\/10.1016\/j.jpba.2011.05.030.","journal-title":"J Pharm Biomed Anal."},{"issue":"9","key":"4054_CR127","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1002\/jps.20144","volume":"93","author":"KM Alsante","year":"2004","unstructured":"Alsante KM, Boutros P, Couturier MA, Sharp TR, Tucker JL, Wilcox GE. Pharmaceutical impurity identification: a case study using a multidisciplinary approach. J Pharm Sci. 2004;93(9):2296\u2013309. https:\/\/doi.org\/10.1002\/jps.20144.","journal-title":"J Pharm Sci"},{"key":"4054_CR128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3897\/pharmacia.72.e158823","volume":"72","author":"E Mateev","year":"2025","unstructured":"Mateev E, Georgieva M, Mateeva A, Zlatkov A. In silico metabolism and toxicity prediction using a knowledge-based approach. Pharmacia. 2025;72:1\u20139. https:\/\/doi.org\/10.3897\/pharmacia.72.e158823.","journal-title":"Pharmacia"},{"issue":"6","key":"4054_CR129","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1177\/1091581809349195","volume":"28","author":"JP Bercu","year":"2009","unstructured":"Bercu JP, Dobo KL, McGovern TJ. Overview of genotoxic impurities in pharmaceutical development. Int J Toxicol. 2009;28(6):353\u201366. https:\/\/doi.org\/10.1177\/1091581809349195.","journal-title":"Int J Toxicol"},{"key":"4054_CR130","unstructured":"International Council for Harmonisation (ICH). Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management. Geneva: ICH; 2019."},{"key":"4054_CR131","doi-asserted-by":"publisher","unstructured":"Chaughule R, Lokur A. Advances in impurity profiling of pharmaceutical formulations. Biomed J Sci Tech Res. 2024;60. https:\/\/doi.org\/10.26717\/BJSTR.2024.60.009393.","DOI":"10.26717\/BJSTR.2024.60.009393"},{"key":"4054_CR132","doi-asserted-by":"publisher","DOI":"10.1515\/revac-2023-0069","volume":"42","author":"BJ Al-Shatti","year":"2023","unstructured":"Al-Shatti BJ, Alsairafi Z, Al-Tannak NF. Green chemistry and its implementation in pharmaceutical analysis. Rev Anal Chem. 2023;42:20230069. https:\/\/doi.org\/10.1515\/revac-2023-0069.","journal-title":"Rev Anal Chem"},{"issue":"5","key":"4054_CR133","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23051065","volume":"23","author":"M Yabr\u00e9","year":"2018","unstructured":"Yabr\u00e9 M, Ferey L, Touridomon Som\u00e9 I, Gaudin K. Greening reversed-phase liquid chromatography methods using alternative solvents for pharmaceutical analysis. Molecules. 2018;23(5):1065. https:\/\/doi.org\/10.3390\/molecules23051065.","journal-title":"Molecules"},{"key":"4054_CR134","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.chroma.2016.07.050","volume":"1467","author":"D Speybrouck","year":"2016","unstructured":"Speybrouck D, Lipka E. Preparative supercritical fluid chromatography: a powerful tool for chiral separations. J Chromatogr A. 2016;1467:33\u201355. https:\/\/doi.org\/10.1016\/j.chroma.2016.07.050.","journal-title":"J Chromatogr A"},{"issue":"12","key":"4054_CR135","doi-asserted-by":"publisher","DOI":"10.1007\/s10404-021-02502-2","volume":"25","author":"P Pattanayak","year":"2021","unstructured":"Pattanayak P, Singh SK, Gulati M, Vishwas S, Kapoor B, Chellappan DK, et al. Microfluidic chips: recent advances, critical strategies in design, applications and future perspectives. Microfluid Nanofluid. 2021;25(12):99. https:\/\/doi.org\/10.1007\/s10404-021-02502-2.","journal-title":"Microfluid Nanofluid"},{"issue":"4","key":"4054_CR136","doi-asserted-by":"publisher","first-page":"14","DOI":"10.51860\/lcgci.2025.212","volume":"2","author":"J Auclair","year":"2025","unstructured":"Auclair J, Rathore AS. Biopharmaceutical characterization in the age of artificial intelligence. LCGC Int. 2025;2(4):14\u20139. https:\/\/doi.org\/10.51860\/lcgci.2025.212.","journal-title":"LCGC Int"},{"issue":"2","key":"4054_CR137","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.yrtph.2015.04.010","volume":"72","author":"N Greene","year":"2015","unstructured":"Greene N, Dobo KL, Kenyon MO, Cheung J, Munzner J, Sobol Z, et al. A practical application of two in silico systems for identification of potentially mutagenic impurities. Regul Toxicol Pharmacol. 2015;72(2):335\u201349. https:\/\/doi.org\/10.1016\/j.yrtph.2015.04.010.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"6","key":"4054_CR138","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1021\/ci0000631","volume":"40","author":"G Roberts","year":"2000","unstructured":"Roberts G, Myatt GJ, Johnson WP, Cross KP, Blower PE. LeadScope: software for exploring large sets of screening data. J Chem Inf Comput Sci. 2000;40(6):1302\u201314. https:\/\/doi.org\/10.1021\/ci0000631.","journal-title":"J Chem Inf Comput Sci"},{"key":"4054_CR139","doi-asserted-by":"publisher","unstructured":"Hemingway R, Baertschi SW, Benstead D, Campbell JM, Coombs M, Huang Z, et al. In silico prediction of pharmaceutical degradation pathways: a benchmarking study using the software program Zeneth. Org Process Res Dev. 2024 Feb 19;28(3). https:\/\/doi.org\/10.1021\/acs.oprd.3c00424.","DOI":"10.1021\/acs.oprd.3c00424"},{"key":"4054_CR140","unstructured":"Bradley C. Integrating AI and machine learning in analytical chemistry. Lab Manager [Internet]. 2025 Aug 18 [cited 2025 Oct 11]. Available from: https:\/\/www.labmanager.com\/integrating-ai-and-machine-learning-in-analytical-chemistry-34221"},{"issue":"28","key":"4054_CR141","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-54716-4","volume":"14","author":"B Cooper","year":"2024","unstructured":"Cooper B, Yang R. An assessment of AcquireX and Compound Discoverer software 3.3 for non-targeted metabolomics. Sci Rep. 2024;14(28):4841. https:\/\/doi.org\/10.1038\/s41598-024-54716-4.","journal-title":"Sci Rep"},{"issue":"2","key":"4054_CR142","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jpba.2011.05.028","volume":"56","author":"JD Stafford","year":"2011","unstructured":"Stafford JD, Maloney TD, Myers DP, Cintron JM, Castle BC. A systematic approach to development of liquid chromatographic impurity methods for pharmaceutical analysis. J Pharm Biomed Anal. 2011;56(2):280\u201392. https:\/\/doi.org\/10.1016\/j.jpba.2011.05.028.","journal-title":"J Pharm Biomed Anal"},{"issue":"4","key":"4054_CR143","doi-asserted-by":"publisher","DOI":"10.3390\/biologics5040035","volume":"5","author":"P Atre","year":"2025","unstructured":"Atre P, Rizvi SAA. Advancements in pharmaceutical lyophilization: integrating QbD, AI, and novel formulation strategies for next-generation biopharmaceuticals. Biologics. 2025;5(4):35. https:\/\/doi.org\/10.3390\/biologics5040035.","journal-title":"Biologics"},{"issue":"6","key":"4054_CR144","doi-asserted-by":"publisher","DOI":"10.3390\/ph16060891","volume":"16","author":"A Blanco-Gonz\u00e1lez","year":"2023","unstructured":"Blanco-Gonz\u00e1lez A, Cabez\u00f3n A, Seco-Gonz\u00e1lez A, Conde-Torres D, Antelo-Riveiro P, Pi\u00f1eiro \u00c1, et al. The role of AI in drug discovery: challenges, opportunities, and strategies. Pharmaceuticals (Basel). 2023;16(6):891. https:\/\/doi.org\/10.3390\/ph16060891.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"4054_CR145","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.jipha.2025.04.001","volume":"3","author":"VN Bhat","year":"2025","unstructured":"Bhat VN, Bharati S, Bothiraja C, Sangshetti J, Gaikwad V. A review on intervention of AI in pharmaceutical sector: revolutionizing drug discovery and manufacturing. Intell Pharm. 2025;3(5):342\u20139. https:\/\/doi.org\/10.1016\/j.jipha.2025.04.001.","journal-title":"Intell Pharm"},{"key":"4054_CR146","unstructured":"Note: This data is mandatory."},{"issue":"6","key":"4054_CR147","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13060919","volume":"13","author":"EJ Kim","year":"2021","unstructured":"Kim EJ, Kim JH, Kim MS, Jeong SH, Choi DH. Process analytical technology tools for monitoring pharmaceutical unit operations: a control strategy for continuous process verification. Pharmaceutics. 2021;13(6):919. https:\/\/doi.org\/10.3390\/pharmaceutics13060919.","journal-title":"Pharmaceutics"},{"issue":"147","key":"4054_CR148","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jpba.2017.09.006","volume":"5","author":"J Cailletaud","year":"2018","unstructured":"Cailletaud J, De Bleye C, Dumont E, Sacr\u00e9 PY, Netchacovitch L, Gut Y, et al. Critical review of surface-enhanced Raman spectroscopy applications in the pharmaceutical field. J Pharm Biomed Anal. 2018;5(147):458\u201372. https:\/\/doi.org\/10.1016\/j.jpba.2017.09.006.","journal-title":"J Pharm Biomed Anal"},{"key":"4054_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119353","volume":"582","author":"D Markl","year":"2020","unstructured":"Markl D, Warman M, Dumarey M, Bergman EL, Folestad S, Shi Z, et al. Review of real-time release testing of pharmaceutical tablets: state-of-the-art, challenges and future perspective. Int J Pharm. 2020;582:119353. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119353.","journal-title":"Int J Pharm"},{"key":"4054_CR150","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2025.126478","volume":"689","author":"SB Londhe","year":"2026","unstructured":"Londhe SB, Kumar S, Agrawal AK, De Beer T, Kumar A, Kumar D. Continuous manufacturing in pharmaceuticals: an integrated approach with NIR and Raman as PAT tools. Int J Pharm. 2026;689:126478. https:\/\/doi.org\/10.1016\/j.ijpharm.2025.126478.","journal-title":"Int J Pharm"},{"issue":"3","key":"4054_CR151","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00216-016-9824-1","volume":"409","author":"KA Esmonde-White","year":"2017","unstructured":"Esmonde-White KA, Cuellar M, Uerpmann C, Lenain B, Lewis IR. Raman spectroscopy as a process analytical technology for pharmaceutical manufacturing and bioprocessing. Anal Bioanal Chem. 2017;409(3):637\u201349. https:\/\/doi.org\/10.1007\/s00216-016-9824-1.","journal-title":"Anal Bioanal Chem"},{"issue":"1","key":"4054_CR152","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1955433","volume":"13","author":"N Furtmann","year":"2021","unstructured":"Furtmann N, Schneider M, Spindler N, Steinmann B, Li Z, Focken I, et al. An end-to-end automated platform process for high-throughput engineering of next-generation multi-specific antibody therapeutics. MAbs. 2021;13(1):1955433. https:\/\/doi.org\/10.1080\/19420862.2021.1955433.","journal-title":"MAbs"},{"issue":"8","key":"4054_CR153","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1007\/s00216-022-03897-9","volume":"414","author":"CE Anderson","year":"2022","unstructured":"Anderson CE, Huynh T, Gasperino DJ, Alonzo LF, Cantera JL, Harston SP, et al. Automated liquid handling robot for rapid lateral flow assay development. Anal Bioanal Chem. 2022;414(8):2607\u201318. https:\/\/doi.org\/10.1007\/s00216-022-03897-9.","journal-title":"Anal Bioanal Chem"},{"issue":"1","key":"4054_CR154","doi-asserted-by":"publisher","DOI":"10.1080\/10408347.2025.2553122","volume":"55","author":"E Alves","year":"2025","unstructured":"Alves E, Gurupadayya BM, Prabhakaran P. Next-generation miniaturized separation platforms: converging detection, automation, and sustainable design for intelligent analytical science. Crit Rev Anal Chem. 2025;55(1):e2553122. https:\/\/doi.org\/10.1080\/10408347.2025.2553122.","journal-title":"Crit Rev Anal Chem"},{"key":"4054_CR155","doi-asserted-by":"publisher","unstructured":"Harvey J, Fleetwood A, Ogilvie R, Teasdale R, Wilcox P, Spanhaak S. Management of organic impurities in small molecule medicinal products: deriving safe limits for use in early development. Regul Toxicol Pharmacol. 2017;84:116\u201323. https:\/\/doi.org\/10.1016\/j.yrtph.2016.12.011..","DOI":"10.1016\/j.yrtph.2016.12.011."}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04054-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04054-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04054-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T20:44:32Z","timestamp":1783629872000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04054-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":155,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4054"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04054-y","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}